Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Beyond Progression in Glioblastoma
NCT01740258Phase 2Completed
- Sponsor
- Duke University
- Start
- Jan 2013
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Duke University. Started Jan 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01740258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01740258.